meRfi®-GM
Paclitaxel + Trastuzumab & Breast Cancer / Mammacarcinoma (HER2 m)
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
The authors found in NCT00542451 - Paclitaxel + Trastuzumab & Breast Cancer / Mammacarcinoma (HER2 m) that adjuvant paclitaxel and trastuzumab lead to great long-term results. Longer follow-ups confirm this. Small HER2-positive tumors have similar PAM50 subtypes as larger ones.
…